Vers une dé-escalade des traitements par immunothérapie des CBNPC avancés: pourquoi, comment ?

Since the advent of immune checkpoint inhibitors (ICIs), the prognosis of non-small cell lung cancer (NSCLC) has undergone a profound transformation. Nonetheless, the use of these agents in terms of dosing, treatment duration, and dosing frequency remains suboptimal. Indeed, a body of evidence suggests that we could potentially use regimens with a lower dose intensity compared to the approved doses. This bears significant implications in terms of cost, and maybe quality of life, and toxicities. The pursuit of optimal immunotherapeutic regimens presents a considerable challenge. This manuscript attempts to synthesize the rationale and modality of optimizing ICI-based treatment and the ongoing trials testing this hypothesis.